HTA

What HTA does

HTA Ltd. is a Bulgaria-headquartered, privately-held consultancy founded in 2015 that delivers health technology assessment (HTA), pharmacoeconomic analysis, real-world data analysis, and value-based healthcare (VBHC) services to pharmaceutical manufacturers, medical device companies, healthcare organizations, and academic institutions across Europe, Africa, the Middle East, and Southeast Asia. The company's core offering is organized around two service pillars: an HTA Services division covering dossier preparation, pharmacoeconomic analysis, RWD and patient registry analysis, PICO surveys, cost-of-illness studies, medical writing, and KOL management; and a VBHC Services division centered on Time-Driven Activity-Based Costing (TDABC), clinical and patient outcome measurement (CROM/PROM), value-based payment scheme design, and IT platform development. Underlying technical capabilities include TDABC methodology with patient journey mapping, local health state utility value application, and epidemiological/biostatistical analysis supported by co-authorship of EQ-5D-5L Bulgarian population norms with the EuroQol Research Foundation.

The business model combines three revenue streams: project-based professional services consulting (the dominant stream, with disclosed Big Pharma clients including Janssen, Novartis, Pfizer, Sanofi, Eli Lilly, AbbVie, Merck, Vertex, Medtronic, and Exceed Orphan); structured 2–6 day training courses sold on a quote basis to healthcare professionals across CEE, West Europe, Middle East, and Africa; and a publishing/e-commerce bookstore selling 15+ specialized titles at €12.80–€30.00 each. The company operates with approximately 15 team members from a Sofia headquarters, holds ISO 9001:2015 and ISO/IEC 27001:2013 certifications, and is staffed by founders and experts with MD, MPH, MBA, and PhD credentials and international training at institutions including Harvard Business School, Glasgow, Barcelona, Copenhagen, Milan, and Vienna. Distribution is direct-sales-led with thought leadership reinforced through 25+ books, 150+ peer-reviewed publications, a ResearchGate profile, and educational programs.

Name

HTA

Legal name

"HTA" Ltd

Website

https://hta.bg

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

HTA Ltd. is a Bulgaria-based consultancy founded in 2015 that provides health technology assessment, pharmacoeconomic analysis, and value-based healthcare services to pharmaceutical manufacturers, medical device companies, and healthcare organizations across Europe, Africa, the Middle East, and Southeast Asia.

Ownership category

akta.pro rank

Product category

Health Technology Assessment Consulting

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Health Services (8000)

akta.pro primary industry

Payer & HTA Engagement (Reimbursement/Submissions) (HLAIAKAD)

akta.pro secondary industries

Economic Evaluation & Health Technology Assessment (Public Programs) (HLAJANAL), Market Access, Pricing & Reimbursement (Evidence Generation) FSP (HLAGAOAN), Health Technology Assessment (HTA) & Reimbursement Policy Bodies (HLAJACAF)

Keywords

• Health technology assessment
• Pharmacoeconomic consulting
• Value-based healthcare
• Market access advisory
• Medical writing services

Headquarters

HQ city

Sofia

HQ country

Bulgaria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. HTA Consulting Services: Core consulting revenue from health technology assessment analyses, HTA dossier preparation, pharmacoeconomic analysis, policy analysis, and advisory services for pharmaceutical and medical device manufacturers.
2. Educational Training Programs: Revenue from professional training courses including Introduction to HTA, Epidemiology & Biostatistics, Market Access, Pricing and Reimbursement, VBHC, and specialized programs. Courses are offered internationally for CEE, West Europe, Middle East, and Africa regions.
3. Publishing and Book Sales: Sale of publications through the e-commerce bookstore, including books on HTA, VBHC, clinical trials, epidemiology, health economics, and related topics. Prices range from approximately €12.80 to €30.00 per book.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

HTA Ltd. is an international consultancy that provides health technology assessment (HTA) services to pharmaceutical manufacturers, medical device companies, and healthcare organizations, including HTA dossier preparation, pharmacoeconomic analysis, real-world data analysis, and reimbursement support. The company also delivers value-based healthcare (VBHC) implementation services (TDABC, outcome measurement), runs professional training courses on HTA, epidemiology, market access, and VBHC, and publishes specialized healthcare books.

Product overview

HTA Ltd. operates as a multi-service consultancy and publishing house in the health technology assessment (HTA) space. Its core offering is a portfolio of consulting services organized around two main pillars: (1) HTA Services — encompassing HTA dossier preparation, pharmacoeconomic analysis, real-world data analysis, societal impact assessment, PICO surveys, cost of illness studies, medical writing, patient registry and epidemiologic data analysis, advisory boards, and KOL management — and (2) VBHC Services — encompassing Time-Driven Activity-Based Costing (TDABC), outcome measurement (CROM and PROM), scientific publication services, telemedicine implementation, patient education, healthcare integration, IT platform building, and value-based payment scheme development. Complementing the consulting services is an Educational Courses division offering structured training programs (Introduction to HTA, Epidemiology & Biostatistics, Market Access, Pricing and Reimbursement, HTA Beyond Market Access, Academic Capacity Building, Value Based Healthcare, and Business Academy for Healthcare Startups) and a Publishing division producing and selling specialized medical and pharmaceutical textbooks and guidebooks (books on clinical trials, gene therapies, oncology, health economics, epidemiology, social medicine, scientific writing, quality of life, integrated care, and HTA best practices). The company serves pharmaceutical manufacturers, medical device companies, healthcare organizations, academia, and health insurers across Europe, Africa, Middle East, and Southeast Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• HTA Dossier Preparation Comprehensive preparation of Health Technology Assessment dossiers for medicines and medical devices, covering scope identification, literature review, clinical effectiveness and safety assessment, economic evaluation, budget impact analysis, and ethical/legal/social implications analysis. The service is targeted at pharmaceutical manufacturers and medical device companies seeking reimbursement approval and market access.
• Pharmacoeconomic Analysis Economic analyses for maintaining reimbursement status of medicines in the Positive Drug List (PDL) and evaluations for inclusion of new medicinal products in the PDL, including cost-effectiveness modeling and local health state utility value applications. Targeted at pharmaceutical manufacturers for market access and reimbursement strategy.
• Real World Data Analysis Comprehensive data solutions covering management and analysis of electronic health records (EHRs), claims and billing activities, product and disease registries, and patient-generated data for evidence-based decision-making. Targeted at pharmaceutical manufacturers and healthcare organizations.
• Time-Driven Activity-Based Costing (TDABC) Precise cost measurement service that attributes costs based on real-time effort of healthcare providers, enabling granular insight into resource utilization and opportunities for cost savings without compromising care quality. Includes patient journey mapping and TDABC optimization results reporting. Targeted at healthcare delivery organizations implementing value-based healthcare models.
• Outcome Measurement Services Collection and analysis of Clinically-Related Outcomes (CROs) and Patient-Related Outcomes (PROs) using a data-driven approach to illuminate the effectiveness of healthcare interventions. Includes CROM (Clinically-Related Outcome Measurement) and PROM (Patient-Related Outcomes Measurement). Targeted at healthcare organizations, pharmaceutical manufacturers, and medical device companies evaluating intervention effectiveness.
• Introduction to HTA Course 2-day introductory course covering key elements and methods of Health Technology Assessment, combining lectures and discussions on HTA principles, biostatistics, clinical epidemiology, patient-relevant outcome measures, systematic reviews, economic evaluation, and decision-analytic modeling. Targeted at healthcare professionals seeking foundational HTA knowledge.
• Epidemiology & Biostatistics Course 3-day course providing theoretical and practical skills in planning and conducting epidemiological studies, including epidemiological analysis and biostatistical analysis skills with practical exercises using modern epidemiology methods. Targeted at healthcare professionals and researchers.
• Market Access Course Course for pharmaceutical industry executives covering European drug policy, HTA dossier preparation, pharmacoeconomic aspects of market access, clinical trial selection, economic analyses, and sensitivity analysis over approximately 2 days. Targeted at pharmaceutical industry executives and market access professionals.
• Pricing and Reimbursement Course Course developing pricing awareness and strategic pricing execution skills, covering cost/price/value concepts, internal and external price referencing, pharmacoeconomic evaluations, negotiation basics, and risk management. Targeted at pharmaceutical product managers and pricing/reimbursement professionals.
• Value Based Healthcare Course Live course covering value-based healthcare principles including integrated practice units, TDABC, process mapping, outcome measurement, economic models, bundled payments, implementation challenges, and global VBHC perspectives over multiple modules. Targeted at healthcare professionals and managers implementing VBHC models.
• Business Academy for Healthcare Startup Entrepreneurs 6-week online and live course equipping aspiring healthcare entrepreneurs with knowledge and skills for launching and managing a successful healthcare business, covering market dynamics, organizational management, financial management, sales and marketing, legal considerations, and human resource management. Targeted at aspiring healthcare startup founders and entrepreneurs.
• Specialized Healthcare Book Publishing Publishing house producing and selling specialized medical and pharmaceutical textbooks and guidebooks including titles on pharmaceutical economics and policy, clinical trials, gene therapies, health economics, epidemiology, social medicine, scientific writing, quality of life, integrated care, HTA best practices, and MitraClip treatment. Prices range from approximately €12.80 to €30.00 per book. Targeted at healthcare professionals, researchers, students, and academic institutions.

Quantifiable outcome

• Positive HTA recommendation from the Health Technology Assessment Commission achieved within 3 months of submission (for selected products)
• +3 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and secondary.

• PRMA Consulting Ltd.coreStrategic or Co-development PartnerPRMA Consulting collaborates with HTA Ltd. on HTA submission dossier preparation for pharmaceutical products. Notable project: preparation of HTA submission dossier for reimbursement of novel oncology product in Bulgaria using PRMA Navigator application. HTA Ltd. provided expert local insights throughout the process and developed dossiers against tight timelines.
• Exceed OrphancoreStrategic or Co-development PartnerMulti-year collaboration focused on rare disease projects where HTA Ltd. provides deep understanding of complexities in small patient populations and high unmet medical needs. HTA Ltd. delivers health technology assessments and pharmacoeconomic analyses tailored to unique challenges of orphan therapies, supporting market access goals across Central & Eastern Europe.
• Medison PharmasecondaryStrategic or Co-development PartnerStrategic collaboration for market access projects in Bulgaria. HTA Ltd. delivered evidence-based reimbursement dossier for product being first in its class for symptomatic treatment of blepharospasm, cervical dystonia, and spasticity. Collaboration enhanced strategic launch plans through scientific and analytical expertise.
• VertexsecondaryStrategic or Co-development PartnerCollaboration for HTA dossier development for Bulgarian market access. HTA Ltd. experts demonstrated extensive knowledge of Bulgarian healthcare and health economic system. Dossiers were high-quality with excellent timelines; team handled last-minute dossier requests requiring significant extra effort.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Parexel International: Global CRO with dedicated market access and HEOR practice offering HTA submissions, evidence generation, and reimbursement strategy across major pharmaceutical markets. Competes with HTA Ltd. for pharma market access budgets, particularly for multi-country submissions.
• Evidera: Multi-national health economics, outcomes research, and market access consultancy (now part of Thermo Fisher Scientific's PPD clinical research services). Evidera offers overlapping HTA dossier preparation, pharmacoeconomic analysis, and real-world evidence services at significantly larger scale, serving as the dominant incumbent in the HEOR space.
• IQVIA: Global life sciences services and data provider with integrated real-world evidence, market access, and HTA consulting capabilities. IQVIA's proprietary data assets and global reach make it a direct competitor for enterprise pharma HTA engagements.
• Cytel: Global biostatistics, health economics, and clinical research services provider. Cytel's HEOR and market access practice competes with HTA Ltd. for pharma health economics engagements, with broader service range and larger team.
• ICON plc (formerly Syneos Health): Global clinical research organization offering health economics and market access services including HTA submissions, evidence synthesis, and value communication. ICON's deep therapeutic expertise and global reach make it a key large-scale competitor for cross-region HTA work.
• RTI Health Solutions: Not-for-profit health economics and outcomes research consultancy providing HTA, market access, and real-world evidence services to pharmaceutical and medical device clients. Comparable in mission and services to HTA Ltd. but with substantially larger bench and international footprint.

Direct peers

• PRMA Consulting: UK-based consultancy specializing in market access, HTA submissions, and pricing/reimbursement strategy for pharmaceutical clients. PRMA Consulting is a named strategic partner of HTA Ltd., having collaborated on Bulgaria HTA submissions using the PRMA Navigator application, making it the most directly comparable peer.
• Syreon Research Institute: Hungarian-founded health economics and outcomes research consultancy with deep CEE expertise in HTA submissions, pharmacoeconomics, and real-world evidence. Most regionally comparable to HTA Ltd. given shared CEE origins and similar service portfolio.
• Valid Insight (a Mtech company): UK-based market access and HTA consultancy providing strategic pricing, reimbursement, and health economics services to pharmaceutical clients. Direct comparable in boutique scale and service scope to HTA Ltd., with similar project-based delivery model.

Emerging players

• PHMR (Pharmora Health Market Research): Specialist market access and health economics consultancy providing HTA, pricing, and reimbursement support. PHMR is a smaller-scale peer with similar boutique positioning and pharma-focused service portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hta-bg
• Facebookfacebook.com/profile.php

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HTA